NO DIFFERENCE IN EFFECTIVENESS WITH EITHER ETANERCEPT ORIGINATOR OR BIOSIMILAR AS FIRST LINE BIOLOGIC TREATMENT FOR RHEUMATOID ARTHRITIS

被引：0
|
作者：
De Cock, D. [1 ]
Davies, R. [1 ]
Kearsley-Fleet, L. [1 ]
Watson, K. [1 ]
Hyrich, K. [1 ,2 ]
机构：
[1] Univ Manchester, Arthrit Res UK Ctr Epidemiol, Manchester, Lancs, England
[2] Cent Manchester NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.4508
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0429
引用
收藏
页码：1377 / 1378
页数：3
相关论文
共 50 条
  • [1] Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
    Kearsley-Fleet, Lianne
    Rokad, Aasiyah
    Tsoi, Man-Fung
    Zhao, Sizheng Steven
    Lunt, Mark
    Watson, Kath D.
    Hyrich, Kimme L.
    [J]. RHEUMATOLOGY, 2023, 62 (12) : 3849 - 3857
  • [2] Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savings
    Deakin, Claire T.
    Littlejohn, Geoffrey O.
    Griffiths, Hedley
    Ciciriello, Sabina
    O'Sullivan, Catherine
    Smith, Tegan
    Youssef, Peter
    Bird, Paul
    [J]. INTERNAL MEDICINE JOURNAL, 2024, 54 (05) : 795 - 801
  • [3] ANALYSIS OF RHEUMATOID ARTHRITIS PATIENTS WHO FAILED THE SWITCH FROM ORIGINATOR ETANERCEPT TO BIOSIMILAR ETANERCEPT IN CROYDON
    Patel, Dimil
    Ahmed, Tazeen J.
    Levy, Sarah
    Rajak, Rizwan
    Sathananthan, Rosh
    Horwood, Natalie
    [J]. RHEUMATOLOGY, 2018, 57
  • [4] SB4 Shows Comparable Short-Term Effectiveness to Its Etanercept Originator As First-Line Biologic Treatment for Patients with Rheumatoid Arthritis in Routine Clinical Care
    De Cock, Diederik
    Kearsley-Fleet, Lianne
    Davies, Rebecca
    Watson, Kath
    Hyrich, Kimme L.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [5] ETANERCEPT ORIGINATOR VERSUS ITS BIOSIMILAR (SB4) FOR THE TREATMENT OF RHEUMATOID ARTHRITIS. ARE THEY TRULY SIMILAR?
    Rokad, Aasiyah
    Kearsley-Fleet, Lianne
    Watson, Kath
    Lunt, Mark
    Hyrich, Kimme L.
    [J]. RHEUMATOLOGY, 2022, 61 : I8 - I8
  • [6] OUTCOMES AFTER SWITCHING FROM ETANERCEPT ORIGINATOR TO ITS BIOSIMILAR (SB4) FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Rokad, Aasiyah
    Kearsley-Fleet, Lianne
    Watson, Kath
    Lunt, Mark
    Hyrich, Kimme L.
    [J]. RHEUMATOLOGY, 2022, 61 : I7 - U568
  • [7] Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data
    Atzeni, Fabiola
    Gerratana, Elisabetta
    Bongiovanni, Sara
    Talotta, Rossella
    Miceli, Gianfranco
    Salaffi, Fausto
    Sarzi-Puttini, Piercarlo
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2021, 23 (06): : 344 - 349
  • [8] COMPARATIVE EFFECTIVENESS OF FIRST-LINE BIOLOGIC MONOTHERAPY IN RHEUMATOID ARTHRITIS
    Silvagni, E.
    Bortoluzzi, A.
    Carrara, G.
    Govoni, M.
    Scire, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 562 - 563
  • [9] Comparing Real-world Retention Rates in a Matched Cohort of Rheumatoid Arthritis Patients Who Either Remained on the Etanercept Originator or Switched to a Biosimilar
    Baganz, Lisa
    Strangfeld, Anja
    Herzer, Peter
    Krause, Andreas
    Tony, Hans-Peter
    Zink, Angela
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [10] COMPARING REAL-WORLD RETENTION RATES IN A MATCHED COHORT OF RHEUMATOID ARTHRITIS PATIENTS WHO EITHER REMAINED ON THE ETANERCEPT ORIGINATOR OR SWITCHED TO A BIOSIMILAR
    Baganz, Lisa
    Strangfeld, Anja
    Herzer, Peter
    Krause, Andreas
    Tony, Hans-Peter
    Zink, Angela
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1136 - 1136
12345